BRPI0515581A - métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer - Google Patents
métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncerInfo
- Publication number
- BRPI0515581A BRPI0515581A BRPI0515581-9A BRPI0515581A BRPI0515581A BR PI0515581 A BRPI0515581 A BR PI0515581A BR PI0515581 A BRPI0515581 A BR PI0515581A BR PI0515581 A BRPI0515581 A BR PI0515581A
- Authority
- BR
- Brazil
- Prior art keywords
- computer program
- methods
- optimization
- analysis
- products
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Abstract
"MéTODOS E PRODUTOS DE PROGRAMA DE COMPUTADOR PARA ANáLISE E OTIMIZAçãO DE CANDIDATOS MARCADORES PARA PROGNóSTICO DE CáNCER". Métodos e produtos de programa de computador para avaliação de e otimização de um ou mais marcadores para uso no estabelecimento de um prognóstico para um paciente sofrendo de uma doença são proporcionados. Mais particularmente, os métodos incluem etapas para avaliação sistemática de uma série de características que podem ser extraídas de uma imagem de uma amostra corporal, tal como uma lâmina histológica, que tenha sido esposta a um ou mais biomarcadores, de modo a estabelecer uma regra de decisão prognóstica baseado em uma ou mais das características extraídas, de modo que a regra de decisão proporciona um prognóstico que é otimamente previsível da expectativa real para o paciente. Assim, os método e produtos de programa de computador proporcionados fornecem prognósticos otimamente previsíveis para auxiliar os médicos a desenvolver estratégias para tratamento eficaz do paciente.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61196504P | 2004-09-22 | 2004-09-22 | |
US61207304P | 2004-09-22 | 2004-09-22 | |
PCT/US2005/033931 WO2006036726A1 (en) | 2004-09-22 | 2005-09-22 | Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0515581A true BRPI0515581A (pt) | 2008-07-29 |
Family
ID=35695736
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515581-9A BRPI0515581A (pt) | 2004-09-22 | 2005-09-22 | métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer |
BRPI0515562-2A BRPI0515562A (pt) | 2004-09-22 | 2005-09-22 | métodos e composições para avaliação do prognóstico do cáncer de mama |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515562-2A BRPI0515562A (pt) | 2004-09-22 | 2005-09-22 | métodos e composições para avaliação do prognóstico do cáncer de mama |
Country Status (11)
Country | Link |
---|---|
US (3) | US7899623B2 (pt) |
EP (2) | EP1805676A1 (pt) |
JP (2) | JP5184087B2 (pt) |
KR (2) | KR20070068401A (pt) |
AT (1) | ATE520988T1 (pt) |
AU (2) | AU2005289728B2 (pt) |
BR (2) | BRPI0515581A (pt) |
CA (2) | CA2580937C (pt) |
IL (2) | IL182063A0 (pt) |
MX (1) | MX2007003502A (pt) |
WO (2) | WO2006036788A2 (pt) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8594410B2 (en) * | 2006-08-28 | 2013-11-26 | Definiens Ag | Context driven image mining to generate image-based biomarkers |
US20050112622A1 (en) * | 2003-08-11 | 2005-05-26 | Ring Brian Z. | Reagents and methods for use in cancer diagnosis, classification and therapy |
US20060003391A1 (en) * | 2003-08-11 | 2006-01-05 | Ring Brian Z | Reagents and methods for use in cancer diagnosis, classification and therapy |
US20080131916A1 (en) * | 2004-08-10 | 2008-06-05 | Ring Brian Z | Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy |
EP2027465A2 (en) | 2006-05-17 | 2009-02-25 | Cellumen, Inc. | Method for automated tissue analysis |
KR100786759B1 (ko) * | 2006-07-07 | 2007-12-18 | 김현기 | Hccr-1을 포함하는 유방암 예후 마커 및 비만 유도조성물 |
WO2008019375A2 (en) * | 2006-08-07 | 2008-02-14 | The Board Of Regents Of The University Of Texas System | Proteomic patterns of cancer prognostic and predictive signatures |
WO2008043104A2 (en) * | 2006-10-06 | 2008-04-10 | Applied Genomics Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
ES2374686T3 (es) | 2007-05-14 | 2012-02-21 | Historx, Inc. | Separación en compartimentos por caracterización de píxel usando agrupamiento de datos de imágenes. |
CA2690633C (en) * | 2007-06-15 | 2015-08-04 | Historx, Inc. | Method and system for standardizing microscope instruments |
US20100221722A1 (en) * | 2007-06-15 | 2010-09-02 | University Of North Carolina At Chapel Hill | Methods for evaluating breast cancer prognosis |
CA2604317C (en) | 2007-08-06 | 2017-02-28 | Historx, Inc. | Methods and system for validating sample images for quantitative immunoassays |
CA2596204C (en) * | 2007-08-07 | 2019-02-26 | Historx, Inc. | Method and system for determining an optimal dilution of a reagent |
US7978258B2 (en) * | 2007-08-31 | 2011-07-12 | Historx, Inc. | Automatic exposure time selection for imaging tissue |
EP2034027A1 (en) * | 2007-09-04 | 2009-03-11 | Siemens Healthcare Diagnostics GmbH | Molecular markers to predict response to chemotherapy and EGFR family inhibiton by targeted strategies |
AU2008294687A1 (en) * | 2007-09-07 | 2009-03-12 | Universite Libre De Bruxelles | Methods and tools for prognosis of cancer in ER- patients |
GB0720113D0 (en) * | 2007-10-15 | 2007-11-28 | Cambridge Cancer Diagnostics L | Diagnostic, prognostic and predictive testing for cancer |
WO2009055480A2 (en) * | 2007-10-22 | 2009-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tgf-beta gene expression signature in cancer prognosis |
WO2009089521A2 (en) * | 2008-01-10 | 2009-07-16 | Nuvera Biosciences, Inc. | Predictors for evaluating response to cancer therapy |
BRPI0914734A2 (pt) * | 2008-06-26 | 2015-10-20 | Dana Farber Cancer Inst Inc | assinaturas e determinantes associados com metástase e métodos de uso dos mesmos |
ES2338843B1 (es) * | 2008-07-02 | 2011-01-24 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Huella genomica de cancer de mama. |
CN102159214A (zh) | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
JP5551702B2 (ja) * | 2008-09-16 | 2014-07-16 | ヒストロックス,インコーポレイテッド. | バイオマーカー発現の再現性のある定量 |
US20100124747A1 (en) * | 2008-11-03 | 2010-05-20 | University Of Southern California | Compositions and methods for diagnosis or prognosis of testicular cancer |
WO2010062705A1 (en) * | 2008-11-03 | 2010-06-03 | Quest Diagnostics Investments Incorporated | Cancer diagnosis using ki-67 |
KR101141103B1 (ko) * | 2009-12-15 | 2012-05-02 | 계명대학교 산학협력단 | 임상진단 결정 규칙 생성 방법 |
US20130065786A1 (en) * | 2010-03-31 | 2013-03-14 | Sividon Diagnostics Gmbh | Method for breast cancer recurrence prediction under endocrine treatment |
EP3508854A1 (en) * | 2010-04-27 | 2019-07-10 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
MX2020004501A (es) | 2010-06-03 | 2021-11-09 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
US9129426B2 (en) | 2010-08-31 | 2015-09-08 | General Electric Company | Motion compensation in image processing |
FR2964744B1 (fr) * | 2010-09-10 | 2015-04-03 | Univ Versailles St Quentin En Yvelines | Test pronostic de l'evolution d'une tumeur solide par analyse d'images |
CA3212002A1 (en) | 2011-03-17 | 2012-09-20 | Cernostics, Inc. | Systems and compositions for diagnosing barrett's esophagus and methods of using the same |
EA201490265A1 (ru) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
WO2013089882A2 (en) * | 2011-09-27 | 2013-06-20 | The Regents Of The University Of Michigan | Recurrent gene fusions in breast cancer |
WO2013067198A1 (en) * | 2011-11-01 | 2013-05-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Gene signature for the prediction of nf-kappab activity |
JP6301258B2 (ja) * | 2011-11-03 | 2018-03-28 | トライパス イメージング インコーポレイテッド | 免疫染色試料を調製するための方法および構成物 |
US8885912B2 (en) * | 2011-11-03 | 2014-11-11 | General Electric Company | Generate percentage of positive cells for biomarkers by normalizing and autothresholding the image intensity produced by immunohistochemistry technique |
WO2013159099A2 (en) * | 2012-04-20 | 2013-10-24 | Memorial Sloan-Kettering Cancer Center | Gene expression profiles associated with metastatic breast cancer |
AU2013255961B2 (en) * | 2012-04-30 | 2017-12-07 | Leica Microsystems Cms Gmbh | Systems and methods for performing quality review scoring of biomarkers and image analysis methods for biological tissue |
US8737709B2 (en) * | 2012-04-30 | 2014-05-27 | General Electric Company | Systems and methods for performing correlation analysis on clinical outcome and characteristics of biological tissue |
BR112015001690A2 (pt) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutações associadas com a resistência a inibidores da tirosina quinase de bruton (btk) |
US20150212087A1 (en) * | 2012-07-27 | 2015-07-30 | Centre Leon Berard | Detection of the ERalpha/Src/PI3K Complex as Predictive Marker in Breast Cancer |
JP2014123230A (ja) * | 2012-12-20 | 2014-07-03 | Sony Corp | 画像処理装置、画像処理方法、及び、プログラム |
CN103136333B (zh) * | 2013-01-29 | 2016-08-10 | 冯力新 | 一种抽象属性的量化评价分析方法 |
CN103293321B (zh) * | 2013-05-27 | 2015-05-13 | 北京大学 | 一种检测dna损伤诱导的早期核仁应激的试剂盒及其应用 |
WO2015023703A1 (en) | 2013-08-12 | 2015-02-19 | Pharmacyclics, Inc. | Methods for the treatment of her2 amplified cancer |
US9519823B2 (en) * | 2013-10-04 | 2016-12-13 | The University Of Manchester | Biomarker method |
US9953417B2 (en) | 2013-10-04 | 2018-04-24 | The University Of Manchester | Biomarker method |
US9785752B1 (en) * | 2014-02-25 | 2017-10-10 | Flagship Biosciences, Inc. | Method for stratifying and selecting candidates for receiving a specific therapeutic approach |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US20170176440A1 (en) * | 2014-03-27 | 2017-06-22 | The Board Of Regents Of The University Of Texas System | Methods and compositions for evaluating breast cancer patients |
WO2015189264A1 (en) | 2014-06-10 | 2015-12-17 | Ventana Medical Systems, Inc. | Predicting breast cancer recurrence directly from image features computed from digitized immunohistopathology tissue slides |
EP3247362A4 (en) | 2014-11-17 | 2018-10-10 | Context Biopharma Inc. | Onapristone extended-release compositions and methods |
EP3227687A4 (en) | 2014-12-05 | 2018-10-24 | Prelude, Inc. | Dcis recurrence and invasive breast cancer |
US20180040120A1 (en) * | 2014-12-29 | 2018-02-08 | Flagship Biosciences, Inc. | Methods for quantitative assessment of mononuclear cells in muscle tissue sections |
KR101765999B1 (ko) | 2015-01-21 | 2017-08-08 | 서울대학교산학협력단 | 암 바이오마커의 성능 평가 장치 및 방법 |
WO2016123525A1 (en) * | 2015-01-30 | 2016-08-04 | Raytheon Company | Apparatus and methods for classifying and counting corn kernels |
AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
WO2017091658A1 (en) | 2015-11-25 | 2017-06-01 | Cernostics, Inc. | Methods of predicting progression of barrett's esophagus |
KR20180091024A (ko) * | 2015-12-02 | 2018-08-14 | 클리어라이트 다이어그노스틱스 엘엘씨 | 암의 검출 및 모니터링을 위해 종양 조직 시료를 준비하고 분석하는 방법 |
JP2019503353A (ja) | 2015-12-15 | 2019-02-07 | コンテキスト・バイオファーマ・インコーポレイテッド | 非晶質オナプリストン組成物およびそれを作製する方法 |
WO2017139367A1 (en) | 2016-02-08 | 2017-08-17 | Imago Systems, Inc. | System and method for the visualization and characterization of objects in images |
EP3430384A4 (en) * | 2016-03-14 | 2019-07-31 | Proteocyte Diagnostics Inc. | AUTOMATED METHOD FOR THE ASSESSMENT OF CANCER RISK BY TISSUE SAMPLES AND SYSTEM THEREFOR |
TWI733772B (zh) | 2016-03-14 | 2021-07-21 | 美商身體邏輯股份有限公司 | 用於合成吲哚環核鹼基結合物之組成物及方法 |
EP3446121A1 (en) * | 2016-04-20 | 2019-02-27 | Eisai Inc. | Prognosis of serous ovarian cancer using biomarkers |
WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
WO2019032558A1 (en) * | 2017-08-07 | 2019-02-14 | Imago Systems, Inc. | SYSTEM AND METHOD FOR VISUALIZATION AND CHARACTERIZATION OF OBJECTS IN IMAGES |
AU2019339508A1 (en) | 2018-09-14 | 2021-04-15 | Prelude Corporation | Method of selection for treatment of subjects at risk of invasive breast cancer |
US20220050996A1 (en) * | 2018-12-15 | 2022-02-17 | The Brigham And Women's Hospital, Inc. | Augmented digital microscopy for lesion analysis |
CA3186353A1 (en) | 2020-07-17 | 2022-01-20 | Bastian LINDER | Prognostic biomarkers for cancer |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
WO1994000591A1 (en) * | 1992-06-26 | 1994-01-06 | Nippon Shinyaku Co., Ltd. | Monoclonal antibody, production process, antibody-producing cell, and diagnostic method |
ATE256313T1 (de) * | 1994-02-14 | 2003-12-15 | Autocyte North Carolina Llc | Automatisiertes cytologisches probenklassifizierungsverfahren |
US5989811A (en) * | 1994-09-29 | 1999-11-23 | Urocor, Inc. | Sextant core biopsy predictive mechanism for non-organ confined disease status |
US5869040A (en) * | 1995-06-07 | 1999-02-09 | Biogen, Inc | Gene therapy methods and compositions |
JP2002514098A (ja) * | 1996-08-25 | 2002-05-14 | センサー インコーポレイテッド | 虹彩取得用イメージのための装置 |
US5798266A (en) * | 1996-08-27 | 1998-08-25 | K-Quay Enterprises, Llc | Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer |
EP0943095A2 (en) * | 1996-11-22 | 1999-09-22 | Shiloov Medical Technologies, Ltd. | A whole blood/mitogen assay for the early detection of a subject with cancer and kit |
JP5213202B2 (ja) * | 1998-10-28 | 2013-06-19 | バイシス・インコーポレーテツド | 細胞アレイならびに遺伝障害マーカーの検出および使用方法 |
US6960449B2 (en) * | 1999-02-10 | 2005-11-01 | Cell Works Diagnostics, Inc. | Class characterization of circulating cancer cells isolated from body fluids and methods of use |
EP1159619A2 (en) * | 1999-03-15 | 2001-12-05 | EOS Biotechnology, Inc. | Methods of diagnosing and treating breast cancer |
US6642009B2 (en) * | 1999-05-17 | 2003-11-04 | Cytyc Health Corporation | Isolated ductal fluid sample |
US20030087265A1 (en) * | 2000-01-21 | 2003-05-08 | Edward Sauter | Specific microarrays for breast cancer screening |
AU781992B2 (en) * | 2000-04-04 | 2005-06-23 | Medical Research Council | Methods involving induced dimerisation by cellular components |
MXPA02010551A (es) * | 2000-04-26 | 2003-09-25 | Univ Kingston | Formulaciones y metodos de uso de mimeticos del oxido nitrico contra fenotipos de celulas malignas. |
GB0011439D0 (en) * | 2000-05-12 | 2000-06-28 | Novartis Res Found | Cancer diagnosis and assays for screening |
AU2001277172A1 (en) * | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-trans protein and related reagents and methods of use thereof |
US6703204B1 (en) * | 2000-07-28 | 2004-03-09 | The Brigham & Women's Hospital, Inc. | Prognostic classification of breast cancer through determination of nucleic acid sequence expression |
DE10101792B4 (de) * | 2001-01-17 | 2004-03-18 | Vivotec Biomedical Technologies Gmbh | Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern |
EP1410011B1 (en) * | 2001-06-18 | 2011-03-23 | Rosetta Inpharmatics LLC | Diagnosis and prognosis of breast cancer patients |
US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
JP3721105B2 (ja) * | 2001-08-22 | 2005-11-30 | 日本電気株式会社 | 組織検査法を利用する胃癌の切除手術後の予後検査方法 |
US7065236B2 (en) * | 2001-09-19 | 2006-06-20 | Tripath Imaging, Inc. | Method for quantitative video-microscopy and associated system and computer software program product |
US6855554B2 (en) * | 2001-09-21 | 2005-02-15 | Board Of Regents, The University Of Texas Systems | Methods and compositions for detection of breast cancer |
US20040002067A1 (en) * | 2001-12-21 | 2004-01-01 | Erlander Mark G. | Breast cancer progression signatures |
US7133547B2 (en) * | 2002-01-24 | 2006-11-07 | Tripath Imaging, Inc. | Method for quantitative video-microscopy and associated system and computer software program product |
AU2003217397A1 (en) * | 2002-02-14 | 2003-09-04 | The Johns Hopkins University School Of Medecine | Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer |
US20040018525A1 (en) * | 2002-05-21 | 2004-01-29 | Bayer Aktiengesellschaft | Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
US20040229299A1 (en) * | 2002-05-21 | 2004-11-18 | Badal M. Youssouf | Intracellular complexes as biomarkers |
US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
AU2004225439A1 (en) * | 2003-04-01 | 2004-10-14 | Monogram Biosciences, Inc. | Intracellular complexes as biomarkers |
CN1905876B (zh) * | 2003-11-17 | 2010-06-09 | 诺瓦提斯公司 | 二肽基肽酶iv抑制剂的用途 |
US20050221398A1 (en) * | 2004-01-16 | 2005-10-06 | Ipsogen, Sas, A Corporation Of France | Protein expression profiling and breast cancer prognosis |
EP1704416A2 (en) * | 2004-01-16 | 2006-09-27 | Ipsogen | Protein expression profiling and breast cancer prognosis |
KR100882249B1 (ko) * | 2004-03-24 | 2009-02-06 | 트리패스 이미징, 인코포레이티드 | 자궁경부 질환의 검사 방법 및 조성물 |
-
2005
- 2005-09-22 AT AT05810348T patent/ATE520988T1/de not_active IP Right Cessation
- 2005-09-22 WO PCT/US2005/034152 patent/WO2006036788A2/en active Application Filing
- 2005-09-22 US US11/233,243 patent/US7899623B2/en active Active
- 2005-09-22 AU AU2005289728A patent/AU2005289728B2/en not_active Ceased
- 2005-09-22 US US11/233,510 patent/US20060063190A1/en not_active Abandoned
- 2005-09-22 BR BRPI0515581-9A patent/BRPI0515581A/pt not_active IP Right Cessation
- 2005-09-22 KR KR1020077009120A patent/KR20070068401A/ko not_active Application Discontinuation
- 2005-09-22 CA CA2580937A patent/CA2580937C/en active Active
- 2005-09-22 CA CA002580795A patent/CA2580795A1/en not_active Abandoned
- 2005-09-22 AU AU2005289756A patent/AU2005289756B2/en active Active
- 2005-09-22 JP JP2007532659A patent/JP5184087B2/ja active Active
- 2005-09-22 BR BRPI0515562-2A patent/BRPI0515562A/pt not_active IP Right Cessation
- 2005-09-22 WO PCT/US2005/033931 patent/WO2006036726A1/en active Application Filing
- 2005-09-22 EP EP05800441A patent/EP1805676A1/en not_active Withdrawn
- 2005-09-22 EP EP05810348A patent/EP1800130B1/en active Active
- 2005-09-22 KR KR1020077009202A patent/KR20070061893A/ko not_active Application Discontinuation
- 2005-09-22 MX MX2007003502A patent/MX2007003502A/es unknown
- 2005-09-22 JP JP2007532688A patent/JP2008513032A/ja active Pending
-
2007
- 2007-03-20 IL IL182063A patent/IL182063A0/en unknown
- 2007-03-20 IL IL182062A patent/IL182062A0/en unknown
-
2009
- 2009-05-14 US US12/466,149 patent/US20090269856A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2580937A1 (en) | 2006-04-06 |
WO2006036726A1 (en) | 2006-04-06 |
US20090269856A1 (en) | 2009-10-29 |
ATE520988T1 (de) | 2011-09-15 |
IL182063A0 (en) | 2008-04-13 |
WO2006036788A2 (en) | 2006-04-06 |
IL182062A0 (en) | 2007-07-24 |
JP2008513793A (ja) | 2008-05-01 |
US20060063190A1 (en) | 2006-03-23 |
CA2580937C (en) | 2016-02-02 |
AU2005289756B2 (en) | 2011-10-13 |
US20060078926A1 (en) | 2006-04-13 |
BRPI0515562A (pt) | 2008-07-29 |
EP1800130B1 (en) | 2011-08-17 |
KR20070068401A (ko) | 2007-06-29 |
AU2005289756A1 (en) | 2006-04-06 |
JP2008513032A (ja) | 2008-05-01 |
EP1800130A2 (en) | 2007-06-27 |
WO2006036788A3 (en) | 2006-08-17 |
KR20070061893A (ko) | 2007-06-14 |
JP5184087B2 (ja) | 2013-04-17 |
AU2005289728B2 (en) | 2011-11-24 |
CA2580795A1 (en) | 2006-04-06 |
AU2005289728A1 (en) | 2006-04-06 |
MX2007003502A (es) | 2007-10-10 |
US7899623B2 (en) | 2011-03-01 |
EP1805676A1 (en) | 2007-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0515581A (pt) | métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer | |
Shipitsin et al. | Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error | |
Cullen et al. | A biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low-and intermediate-risk prostate cancer | |
Rouzier et al. | Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses | |
WO2005100999A3 (en) | Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer | |
Lotan et al. | Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors | |
Peng et al. | An expression signature at diagnosis to estimate prostate cancer patients’ overall survival | |
MXPA06012232A (es) | Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas. | |
Ravvaz et al. | Predicting nonmuscle invasive bladder cancer recurrence and progression in a United States population | |
Van den Broeck et al. | Validation of the Decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery | |
Saldanha et al. | 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma | |
BR112022004094A2 (pt) | Biomarcadores para predizer atividade de doença de esclerose múltipla | |
Sonpavde et al. | Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy | |
CN105705653A (zh) | 针对膀胱癌的dna甲基化生物标志物 | |
Cao et al. | Evaluation of the eighth edition of the American Joint Committee on Cancer TNM staging system for gastric cancer: an analysis of 7371 patients in the SEER database | |
Wong et al. | International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy | |
Zeng et al. | Development and external validation of a nomogram predicting prognosis of upper tract urothelial carcinoma after radical nephroureterectomy | |
Vesely et al. | Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome | |
Mannelli et al. | Nomograms predictive for oncological outcomes in malignant parotid tumours: recurrence and mortality rates of 228 patients from a single institution | |
Zheng et al. | Application of nomograms to predict overall and cancer-specific survival in patients with chordoma | |
KR101771042B1 (ko) | 질병 관련 유전자 탐색 장치 및 그 방법 | |
Lin et al. | Digital Quantification of Tumor Cellularity as a Novel Prognostic feature of non–small cell lung carcinoma | |
Ibrahim et al. | Artificial Intelligence-Based Mitosis Scoring in Breast Cancer: Clinical Application | |
Leze et al. | Advantages of evaluating mean nuclear volume as an adjunct parameter in prostate cancer | |
Schmidt et al. | DNA methylation profiling in mummified human remains from the eighteenth-century |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |